Cargando…

Chronic helminth infection does not impair immune response to malaria transmission blocking vaccine Pfs230D1-EPA/Alhydrogel® in mice

INTRODUCTION: Malaria transmission blocking vaccines (TBV) are innovative approaches that aim to induce immunity in humans against Plasmodium during mosquito stage, neutralizing the capacity of the infected vectors to transmit malaria. Pfs230D1-EPA/Alhydrogel®, a promising protein-protein conjugate...

Descripción completa

Detalles Bibliográficos
Autores principales: Coelho, Camila H., Gazzinelli-Guimaraes, Pedro Henrique, Howard, Jennifer, Barnafo, Emma, Alani, Nada A.H., Muratova, Olga, McCormack, Ashley, Kelnhofer, Emily, Urban, Joseph F., Narum, David L., Anderson, Charles, Langhorne, Jean, Nutman, Thomas B., Duffy, Patrick E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382667/
https://www.ncbi.nlm.nih.gov/pubmed/30685251
http://dx.doi.org/10.1016/j.vaccine.2019.01.027
_version_ 1783396687918661632
author Coelho, Camila H.
Gazzinelli-Guimaraes, Pedro Henrique
Howard, Jennifer
Barnafo, Emma
Alani, Nada A.H.
Muratova, Olga
McCormack, Ashley
Kelnhofer, Emily
Urban, Joseph F.
Narum, David L.
Anderson, Charles
Langhorne, Jean
Nutman, Thomas B.
Duffy, Patrick E.
author_facet Coelho, Camila H.
Gazzinelli-Guimaraes, Pedro Henrique
Howard, Jennifer
Barnafo, Emma
Alani, Nada A.H.
Muratova, Olga
McCormack, Ashley
Kelnhofer, Emily
Urban, Joseph F.
Narum, David L.
Anderson, Charles
Langhorne, Jean
Nutman, Thomas B.
Duffy, Patrick E.
author_sort Coelho, Camila H.
collection PubMed
description INTRODUCTION: Malaria transmission blocking vaccines (TBV) are innovative approaches that aim to induce immunity in humans against Plasmodium during mosquito stage, neutralizing the capacity of the infected vectors to transmit malaria. Pfs230D1-EPA/Alhydrogel®, a promising protein-protein conjugate malaria TBV, is currently being tested in human clinical trials in areas where P. falciparum malaria is coendemic with helminth parasites. Helminths are complex metazoans that share the master capacity to downregulate the host immune response towards themselves and also to bystander antigens, including vaccines. However, it is not known whether the activity of a protein-based malaria TBV may be affected by a chronic helminth infection. METHODS: Using an experimental murine model for a chronic helminth infection (Heligmosomoides polygyrus bakeri - Hpb), we evaluated whether prior infection alters the activity of Pfs230D1-EPA/Alhydrogel® TBV in mice. RESULTS: After establishment of a chronic infection, characterized by a marked increase of parasite antigen-specific IgG1, IgA and IgE antibody responses, concomitant with an increase of systemic IL-10, IL-5 and IL-6 levels, the Hpb-infected mice were immunized with Pfs230D1-EPA/Alhydrogel® and the vaccine-specific immune response was compared with that in non-infected immunized mice. TBV immunizations induced an elevated vaccine specific-antibody response, however Pfs230D1 specific-IgG levels were similar between infected and uninfected mice at days 15, 25 and 35 post-vaccination. Absolute numbers of Pfs230D1-activated B cells generated in response to the vaccine were also similar among the vaccinated groups. Finally, vaccine activity assessed by reduction of oocyst number in P. falciparum infected mosquitoes was similar between Hpb-infected and immunized mice with non-infected immunized mice. CONCLUSION: Pfs230D1-EPA/Alhydrogel® efficacy is not impaired by a chronic helminth infection in mice.
format Online
Article
Text
id pubmed-6382667
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier Science
record_format MEDLINE/PubMed
spelling pubmed-63826672019-03-01 Chronic helminth infection does not impair immune response to malaria transmission blocking vaccine Pfs230D1-EPA/Alhydrogel® in mice Coelho, Camila H. Gazzinelli-Guimaraes, Pedro Henrique Howard, Jennifer Barnafo, Emma Alani, Nada A.H. Muratova, Olga McCormack, Ashley Kelnhofer, Emily Urban, Joseph F. Narum, David L. Anderson, Charles Langhorne, Jean Nutman, Thomas B. Duffy, Patrick E. Vaccine Article INTRODUCTION: Malaria transmission blocking vaccines (TBV) are innovative approaches that aim to induce immunity in humans against Plasmodium during mosquito stage, neutralizing the capacity of the infected vectors to transmit malaria. Pfs230D1-EPA/Alhydrogel®, a promising protein-protein conjugate malaria TBV, is currently being tested in human clinical trials in areas where P. falciparum malaria is coendemic with helminth parasites. Helminths are complex metazoans that share the master capacity to downregulate the host immune response towards themselves and also to bystander antigens, including vaccines. However, it is not known whether the activity of a protein-based malaria TBV may be affected by a chronic helminth infection. METHODS: Using an experimental murine model for a chronic helminth infection (Heligmosomoides polygyrus bakeri - Hpb), we evaluated whether prior infection alters the activity of Pfs230D1-EPA/Alhydrogel® TBV in mice. RESULTS: After establishment of a chronic infection, characterized by a marked increase of parasite antigen-specific IgG1, IgA and IgE antibody responses, concomitant with an increase of systemic IL-10, IL-5 and IL-6 levels, the Hpb-infected mice were immunized with Pfs230D1-EPA/Alhydrogel® and the vaccine-specific immune response was compared with that in non-infected immunized mice. TBV immunizations induced an elevated vaccine specific-antibody response, however Pfs230D1 specific-IgG levels were similar between infected and uninfected mice at days 15, 25 and 35 post-vaccination. Absolute numbers of Pfs230D1-activated B cells generated in response to the vaccine were also similar among the vaccinated groups. Finally, vaccine activity assessed by reduction of oocyst number in P. falciparum infected mosquitoes was similar between Hpb-infected and immunized mice with non-infected immunized mice. CONCLUSION: Pfs230D1-EPA/Alhydrogel® efficacy is not impaired by a chronic helminth infection in mice. Elsevier Science 2019-02-14 /pmc/articles/PMC6382667/ /pubmed/30685251 http://dx.doi.org/10.1016/j.vaccine.2019.01.027 Text en http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Coelho, Camila H.
Gazzinelli-Guimaraes, Pedro Henrique
Howard, Jennifer
Barnafo, Emma
Alani, Nada A.H.
Muratova, Olga
McCormack, Ashley
Kelnhofer, Emily
Urban, Joseph F.
Narum, David L.
Anderson, Charles
Langhorne, Jean
Nutman, Thomas B.
Duffy, Patrick E.
Chronic helminth infection does not impair immune response to malaria transmission blocking vaccine Pfs230D1-EPA/Alhydrogel® in mice
title Chronic helminth infection does not impair immune response to malaria transmission blocking vaccine Pfs230D1-EPA/Alhydrogel® in mice
title_full Chronic helminth infection does not impair immune response to malaria transmission blocking vaccine Pfs230D1-EPA/Alhydrogel® in mice
title_fullStr Chronic helminth infection does not impair immune response to malaria transmission blocking vaccine Pfs230D1-EPA/Alhydrogel® in mice
title_full_unstemmed Chronic helminth infection does not impair immune response to malaria transmission blocking vaccine Pfs230D1-EPA/Alhydrogel® in mice
title_short Chronic helminth infection does not impair immune response to malaria transmission blocking vaccine Pfs230D1-EPA/Alhydrogel® in mice
title_sort chronic helminth infection does not impair immune response to malaria transmission blocking vaccine pfs230d1-epa/alhydrogel® in mice
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382667/
https://www.ncbi.nlm.nih.gov/pubmed/30685251
http://dx.doi.org/10.1016/j.vaccine.2019.01.027
work_keys_str_mv AT coelhocamilah chronichelminthinfectiondoesnotimpairimmuneresponsetomalariatransmissionblockingvaccinepfs230d1epaalhydrogelinmice
AT gazzinelliguimaraespedrohenrique chronichelminthinfectiondoesnotimpairimmuneresponsetomalariatransmissionblockingvaccinepfs230d1epaalhydrogelinmice
AT howardjennifer chronichelminthinfectiondoesnotimpairimmuneresponsetomalariatransmissionblockingvaccinepfs230d1epaalhydrogelinmice
AT barnafoemma chronichelminthinfectiondoesnotimpairimmuneresponsetomalariatransmissionblockingvaccinepfs230d1epaalhydrogelinmice
AT alaninadaah chronichelminthinfectiondoesnotimpairimmuneresponsetomalariatransmissionblockingvaccinepfs230d1epaalhydrogelinmice
AT muratovaolga chronichelminthinfectiondoesnotimpairimmuneresponsetomalariatransmissionblockingvaccinepfs230d1epaalhydrogelinmice
AT mccormackashley chronichelminthinfectiondoesnotimpairimmuneresponsetomalariatransmissionblockingvaccinepfs230d1epaalhydrogelinmice
AT kelnhoferemily chronichelminthinfectiondoesnotimpairimmuneresponsetomalariatransmissionblockingvaccinepfs230d1epaalhydrogelinmice
AT urbanjosephf chronichelminthinfectiondoesnotimpairimmuneresponsetomalariatransmissionblockingvaccinepfs230d1epaalhydrogelinmice
AT narumdavidl chronichelminthinfectiondoesnotimpairimmuneresponsetomalariatransmissionblockingvaccinepfs230d1epaalhydrogelinmice
AT andersoncharles chronichelminthinfectiondoesnotimpairimmuneresponsetomalariatransmissionblockingvaccinepfs230d1epaalhydrogelinmice
AT langhornejean chronichelminthinfectiondoesnotimpairimmuneresponsetomalariatransmissionblockingvaccinepfs230d1epaalhydrogelinmice
AT nutmanthomasb chronichelminthinfectiondoesnotimpairimmuneresponsetomalariatransmissionblockingvaccinepfs230d1epaalhydrogelinmice
AT duffypatricke chronichelminthinfectiondoesnotimpairimmuneresponsetomalariatransmissionblockingvaccinepfs230d1epaalhydrogelinmice